EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy

Sharenya Chelvaretnam, Kol Thida Mom, Carlos Andres Palma Henriquez iD, Quang Pham iD, Amirah Fitri, Sadman Bhuiyan, Mozhgan Shojaee, Kartini Asari, Hiba Rashid, Leearne Hinch, Ramin Khanabdali, Gregory Rice

International Journal of Molecular Sciences · 25.02.2026 · 27 (5) · 2163

DOI: 10.3390/ijms27052163 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.02.2026. Verfasst von Sharenya Chelvaretnam und 11 weiteren Autor:innen. Beteiligte Einrichtung: INOVIQ Ltd., Melbourne, VIC 3168, Australia. Hauptthemen laut MEDLINE: Extracellular Vesicles, Neoplasms, Receptors, Chimeric Antigen, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy has experienced substantial progress in recent years, particularly with the advancement of chimeric antigen receptor (CAR) technology, which enables immune cells to selectively target tumor-associated antigens. CARs, now in their fifth generation, are engineered by combining monoclonal antibody fragments with signaling and co-stimulatory domains and have been successfully applied to T cell, natural killer (NK) cell, and macrophage-based therapies. Notable clinical successes, such as tisagenlecleucel and lisocabtagene maraleucel underscore the therapeutic potential of CAR-T, CAR-NK and CAR-macrophages (CAR-Ms), which are currently being evaluated in numerous clinical trials. One promising extension of this approach involves the use of extracellular vesicles (EVs) derived from these immune cells. These nano-sized vesicles offer a cell-free platform to deliver diverse anticancer mediators, addressing the complex and dynamic nature of tumor environments. In this review, we examine the therapeutic potential and immunogenic properties of CAR-derived EVs, along with their role in modulating immune responses. Furthermore, we explore their application as targeted delivery vehicles for chemotherapeutic agents, with the goal of enhancing anti-tumor efficacy while minimizing systemic toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesNeoplasmsReceptors, Chimeric AntigenImmunotherapyImmunotherapy, AdoptiveHumansAnimalsT-Lymphocytes

Stichwörter der Autor:innen

cancerchimeric antigen receptorextracellular vesiclesimmunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • INOVIQ Ltd., Melbourne, VIC 3168, Australia.
  • Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4006, Australia.

ORCID-Profile: Carlos Andres Palma Henriquez, Quang Pham

Zitieren

APA

Chelvaretnam, S., Mom, K. T., Palma Henriquez, C. A., Pham, Q., Fitri, A., Bhuiyan, S., Shojaee, M., Asari, K., Rashid, H., Hinch, L., Khanabdali, R., & Rice, G. (2026). Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy. International Journal of Molecular Sciences, 27(5), 2163. https://doi.org/10.3390/ijms27052163

Vancouver

Chelvaretnam S, Mom KT, Palma Henriquez CA, Pham Q, Fitri A, Bhuiyan S, et al. Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy. International Journal of Molecular Sciences. 2026;27(5):2163. doi:10.3390/ijms27052163

BibTeX
@article{Chelvaretnam2026,
  author = {Chelvaretnam, Sharenya and Mom, Kol Thida and Palma Henriquez, Carlos Andres and Pham, Quang and Fitri, Amirah and Bhuiyan, Sadman and Shojaee, Mozhgan and Asari, Kartini and Rashid, Hiba and Hinch, Leearne and Khanabdali, Ramin and Rice, Gregory},
  title = {Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {5},
  pages = {2163},
  doi = {10.3390/ijms27052163}
}
Kostenlos starten →